Dr. Howard Burris on Patient-Reported Outcomes of MARIANNE

Howard A "Skip" Burris, III, MD
Published: Friday, Jul 08, 2016



Howard A. “Skip” Burris, MD president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discuses the MARIANNE trial in advanced HER2-positive breast cancer.  
 
In the overall study results, patients with locally advanced or untreated metastatic HER2-positive disease were randomized to receive T-DM1 plus pertuzumab (Perjeta), T-DM1 alone, or trastuzumab (Herceptin) plus a taxane-based agent. Phase III results of the trial showed that neither T-DM1 arm was associated with improved outcomes compared with the trastuzumab/taxane arm.
 
However, in patient-reported outcomes of the trial, patients with advanced HER2-positive breast cancer who received treatment with trastuzumab emtanzssine were found to have a lower incidence of treatment-related adverse events.
 
These means that trastuzumab emtanzssine is still a good option for patients with advanced HER2-positive breast cancer, says Burris.
 
SELECTED
LANGUAGE


Howard A. “Skip” Burris, MD president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discuses the MARIANNE trial in advanced HER2-positive breast cancer.  
 
In the overall study results, patients with locally advanced or untreated metastatic HER2-positive disease were randomized to receive T-DM1 plus pertuzumab (Perjeta), T-DM1 alone, or trastuzumab (Herceptin) plus a taxane-based agent. Phase III results of the trial showed that neither T-DM1 arm was associated with improved outcomes compared with the trastuzumab/taxane arm.
 
However, in patient-reported outcomes of the trial, patients with advanced HER2-positive breast cancer who received treatment with trastuzumab emtanzssine were found to have a lower incidence of treatment-related adverse events.
 
These means that trastuzumab emtanzssine is still a good option for patients with advanced HER2-positive breast cancer, says Burris.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x